Unicycive Therapeutics
UNCY
12 hedge funds and large institutions have $1.48M invested in Unicycive Therapeutics in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
9% more funds holding
Funds holding: 11 → 12 (+1)
0.02% more ownership
Funds ownership: 0.75% → 0.77% (+0.02%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
36% less capital invested
Capital invested by funds: $2.3M → $1.48M (-$823K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Truist Financial
Charlotte,
North Carolina
|
+$54.9K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$54.5K |
| 3 |
BlackRock
New York
|
+$11.9K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.62K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$67.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$11K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NCM
1
Nantahala Capital Management
New Canaan,
Connecticut
| $826K | -$67.5K | -4,613 | -7% |
|
|
BOTOTLSJU
2
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
| $319K | – | – | – |
|
|
AC
3
Ayrton Capital
Westport,
Connecticut
| $99K | – | – | – |
|
|
4
Citadel Advisors
Miami,
Florida
| $48K | +$54.5K | +3,720 | New |
|
|
5
Truist Financial
Charlotte,
North Carolina
| $48K | +$54.9K | +3,746 | New |
|
6
Geode Capital Management
Boston,
Massachusetts
| $33K | – | – | – |
|
|
7
BlackRock
New York
| $31K | +$11.9K | +812 | +51% |
|
8
Vanguard Group
Malvern,
Pennsylvania
| $29K | – | – | – |
|
|
FWM
9
Frontier Wealth Management
Kansas City,
Missouri
| $20K | – | – | – |
|
|
TCM
10
Tandem Capital Management
Woodcliff Lake,
New Jersey
| $17K | – | – | – |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| $5K | +$5.62K | +384 | New |
|
|
12
UBS Group
Zurich,
Switzerland
| – | -$11K | -527 | Closed |
|
UNCY Hedge Fund Activity: Q1 2022 in Review
12 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q1 2022, worth a combined $1.48M — down 36% from $2.3M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new UNCY positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Truist Financial, opening a new position worth an estimated $54.9K. The largest seller was Nantahala Capital Management, cutting an estimated $67.5K.
- 12 institutional investors held Unicycive Therapeutics (UNCY) as of Q1 2022, up from 11 in Q4 2021.
- Funds reported $1.48M of Unicycive Therapeutics stock for Q1 2022, down 36% quarter-over-quarter.
- 3 funds opened new Unicycive Therapeutics positions in Q1 2022 and 2 closed out, a net change of +1 holder.
- The largest Unicycive Therapeutics buyer in Q1 2022 was Truist Financial, an estimated $54.9K added.
- The largest Unicycive Therapeutics seller in Q1 2022 was Nantahala Capital Management, an estimated $67.5K sold.
Based on aggregated 13F filings for Q1 2022.